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Abstract
Background: The purpose of this study was to investigate whether localized peripheral inflammation, such as
osteoarthritis, contributes to neuroinflammation and neurodegenerative disease in vivo.
Methods: We employed the inducible Col1-IL1b
XAT mouse model of osteoarthritis, in which induction of
osteoarthritis in the knees and temporomandibular joints resulted in astrocyte and microglial activation in the
brain, accompanied by upregulation of inflammation-related gene expression. The biological significance of the link
between peripheral and brain inflammation was explored in the APP/PS1 mouse model of Alzheimer’s disease (AD)
whereby osteoarthritis resulted in neuroinflammation as well as exacerbation and acceleration of AD pathology.
Results: Induction of osteoarthritis exacerbated and accelerated the development of neuroinflammation, as
assessed by glial cell activation and quantification of inflammation-related mRNAs, as well as Ab pathology,
assessed by the number and size of amyloid plaques, in the APP/PS1; Col1-IL1b
XAT compound transgenic mouse.
Conclusion: This work supports a model by which peripheral inflammation triggers the development of
neuroinflammation and subsequently the induction of AD pathology. Better understanding of the link between
peripheral localized inflammation, whether in the form of osteoarthritis, atherosclerosis or other conditions, and
brain inflammation, may prove critical to our understanding of the pathophysiology of disorders such as
Alzheimer’s, Parkinson’s and other neurodegenerative diseases.
Background
Systemic (peripheral) inflammation may be associated
with increased risk for Alzheimer’s Disease (AD) pathol-
ogy. In particular, a number of investigators have
reported associations between serum levels of pro-
inflammatory cytokines and other markers, including
interleukin (IL)-1b, IL-6, tumor necrosis factor (TNF)a,
C-reactive protein and a1-antichymotrypsin, with
increased risk for dementia and AD [1-6]. Increased risk
for AD was also observed in people homozygous for
allele 2 of IL-1b (+3953), a variant previously associated
with increased IL-1b secretion in vitro [7,8].
In animal models of neurodegeneration, experimen-
tally-induced acute systemic inflammation led to the
release of proinflammatory factors in the central ner-
vous system that exacerbated neurodegeneration [9,10].
In another study, repeated intraperitoneal lipopolysac-
charide (LPS) injection in wild type male mice resulted
in accumulation of Ab1-42 in the hippocampus and cer-
ebral cortex [11]. In contrast, LPS administration to AD
mouse models has given mixed results, with some inves-
tigators reporting exacerbation [12-14] and others
improvement of pathology due to an inflammation-
induced phagocytic activity [15-17]. To this end, over-
expression of inflammatory cytokines in the brain of AD
mouse models also resulted in alleviation of AD pathol-
ogy [18], including our own where sustained expression
of interleukin-1b (IL-1b) in mouse hippocampus pro-
moted plaque clearance in the APP/PS1 double trans-
genic mouse model [19].
But how is peripheral inflammation linked to AD
pathology? Osteoarthritis (OA) in particular manifests as
a slowly progressing debilitating disease that affects one
or more joints of the body. Clinical symptoms include
pain, swelling, joint enlargement and decreased range of
joint motion. Substantial evidence confirms the role of
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tors in disease development [20-22]. To explore whether
osteoarthritis contributest ot h ed e v e l o p m e n to fn e u -
roinflammation and possibly AD pathology, we
employed somatic mosaic expression of IL-1b in the
knees and temporomandibular joints of the Col-IL1b
XAT
transgenic mouse model of osteoarthritis [23-25]. We
report that localized induction of osteoarthritis in the
young adult APP/PS1 mouse model of AD leads to glial
activation as well as acceleration and exacerbation of
AD plaque pathology. A link between peripheral and
brain inflammation may prove critical to our under-
standing of neurodegenerative disorders and treatments
thereof.
Methods
Animal studies
All experimental protocols involving animals were
reviewed and approved by the University Committee on
Animal Resources (IACUC). Employing a somatic
mosaic analysis approach, we induced osteoarthritis in
knees and temporomandibular joints (TMJs) of the
Col1-IL1b
XAT mouse model [23-25]. Under anesthesia
(ketamine 40 mg/kg intraperitoneally), 2 month old
Col1-IL1b
XAT transgenic mice received bilateral intra-
articular injections of FIV(Cre) in both knees and tem-
poromandibular joints (10 μL solution containing a total
of 10
6 infectious particles per joint) as previously
described. In addition, Col1-IL1b
XAT mice that received
equal dose/volume of FIV(gfp) or saline served as con-
trols. Two or 6 months after viral transduction, the
mice were deeply anesthetized (pentobarbital 100 mg/Kg
intraperitoneally) and decapitated. A total of 32 mice
was employed in this study: 13 Col1-IL1b
XAT mice
injected with FIV(Cre), 13 mice injected with FIV(gfp)
and 6 mice injected with saline intra-articularly. Their
brains were harvested and split sagitally in two halves:
one half was fixed by immersion in 10% formalin for
immunohistochemical analysis and the other half was
immersed into Trizol reagent (Invitrogen) for RNA
extraction. In addition, blood serum was collected for
assessment of human IL-1b and murine IL-6 levels by
ELISA (R&D Systems, Minneapolis MN).
The biological significance of arthritis-induced neu-
roinflammation was evaluated in the APP/PS1 mouse
model of Alzheimer’sd i s e a s e[ 2 6 ] .T ot h i se n d ,A P P /
PS1; Col1-IL1b
XAT compound transgenic mice were
generated on the C57/BL6 background strain by cross-
ing Col1-IL1b
XAT transgenic mice into the APP/PS1
(B6C3-Tg(APPswe, PSEN1dE9)85Dbo/J) mouse model
obtained from The Jackson Laboratories (stock 4462;
Bar Harbor, ME). Osteoarthritis was induced in the
knees and TMJs of 2 month old APP/PS1; Col1-IL1b
XAT
mice by FIV(Cre) injection (10 μL solution containing a
total of 10
6 infectious particles per joint) under anesthe-
sia. The mice were sacrificed 2 and 6 months following
viral transduction of the knees and TMJs, at the age of
4 and 8 months, respectively. A total of 38 mice was
employed in this study, including 18 experimental (APP/
PS1; Col1-IL1b
XAT) mice with arthritis and 20 (APP/
PS1) control mice: The male:female ratio was 1:1.
Histology
Brain histology sections were cut on a freezing micro-
tome into 18 μm thick sections, which were collected
on Superfrost
® glass slides. Immunohistochemical analy-
sis for glial fibrillary acidic protein (GFAP) and class II
major histocompatibility complex (MHC-II) was per-
formed using a rabbit anti-GFAP (human) polyclonal
antibody (1:1,000 dilution; Dako USA, Carpinteria, CA),
and a rat anti-MHC-II (mouse) antibody (1:500 dilution;
Bachem, Torrance CA; clone ER-TR3), respectively. Ab
plaques were identified by immunohistochemistry
employing a mouse anti- b-amyloid (rodent) monoclonal
antibody (1:400 dilution; SIGNET, El Monte, CA; clone
6E10). For Ab staining, brain sections were treated in
90% formic acetate aqueous solution for 5 minutes prior
to immunohistochemistry. Primary antibodies were
coupled with appropriate secondary antibodies: goat
anti-rabbit IgG biotin-conjugated and goat anti-rat IgG
biotin-conjugated antibodies, respectively (Jackson
Immunoresearch, West Grove PA). Visualization was
performed utilizing DAB (3,3-diaminobenzidine)-nickel
as chromagen. Slides were dehydrated through multiple
ethanol solutions, cleared through xylene and cover-
slipped using DPX permanent mounting medium
(Fluka, Neu-Ulm, Switzerland). Tissue sections were
examined under a BX51 Olympus light microscope and
color microphotographic images were captured. The
total numbers of GFAP
+,M H C - I I
+ cells were counted
in 10 random microscopic fields (40×) and cell counts
were expressed as averages (± standard errors of mean)
for each antigen. The number of Ab plaques were
counted on histology sections, divided into an anterior,
middle and posterior third of the brain and expressed as
averages (± standard errors of mean) for each animal
group. Each brain was halved midsagittally and sec-
tioned on a cryostat into 20 μm thick coronal sections
collected sequentially onto 12 Permafrost
® glass slides,
such that a total of 24 sections were on each glass slide
and each section represented an area of the brain that
was 240 μm apart from each neighboring section. The
first 8 sections on each glass slide represented the ante-
rior portion of the brain, the next 8 sections the middle
and the last 8 sections represented the posterior third of
the brain in our cell counting.
The knees and temporomandibular joints were also
harvested, defleshed and decalcified by immersion in an
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tation. The joints were then processed on a RHS-1
microwave tissue processor, after which the samples
were embedded in paraffin, cut on a microtome as 3 μm
thick sections and collected on glass slides. Joint histo-
pathology was evaluated in sections stained by Alcian
blue-orange G histochemistry using a scale 0-5 pre-
viously described [23,24]. Articular cloning was assessed
by microscopy and counted as 2 or more chondrocytes
present in a single lacuna in each joint section [23].
Antibodies used in these experiments include a rabbit
anti-human mature IL-1b (1:100; Abcam, Cambridge
MA), and rabbit anti-b-galactosidase (bacterial) (1:1,000;
Sigma; St. Louis, MO). Cre recombinase expression was
assessed with an antibody raised against its V5 fusion
epitope (1:500; rat anti-V5; Invitrogen).
RT-PCR
Quantification of mRNA levels was accomplished using
an iCycler (Bio-Rad) and real time qRT-PCR with Taq-
man probes constructed with FAM (fluorescent marker)
and Blackhole I quencher (Biosearch Technologies,
Novato CA) as previously described [23]. PCR reactions
were performed in a volume of 25 μl and contained iQ
Supermix (Bio-Rad, Hercules CA), 0.625 U Taq, 0.8 mM
dNTP, 3 mM Mg
2+, 0.2-0.6 μM concentrations of each
primer, 10-100 nM probe and 1 μl of cDNA sample. To
correct for variations in starting RNA values, the level
of ribosomal 18S RNA or GAPDH RNA was determined
for all samples and used to normalize all subsequent
RNA determinations. Normalized threshold cycle (Ct)
values were then transformed, using the function-
expression = (1+ e) Ct, in order to determine the rela-
tive differences in transcript expression. Using this
method, transcript levels for IL-1b,T N F a,G F A Pa n d
MHC-II were measured.
Behavioral Analyses
Grooming behavior was evaluated by adapting a method
previously described [23]. In brief, mice were placed in a
custom-made cage (12"x12"x12”)w i t h4m i r r o r e dw a l l s .
T h ec a g el a c k e dar o o fs ot h a tt h em i c ec o u l db e
observed and recorded. Each mouse was transferred into
the aforementioned observation chamber containing
bedding from its original cage and was allowed a 30 min
habituation period to minimize stress. Behaviors were
recorded on a video-tape for a period of 60 minutes
using a Sony digital recorder (Digital Handycam/Digital
8) with a Cokin macro digital lens (mode C043) added
for image enlargement. The mouse was then returned to
its original cage. Grooming was measured during play-
back by counting the number of seconds a mouse
rubbed its face and/or flinched its head during the ses-
sion. The mice did not have access to food or water
during the brief testing period. Behavioral evaluation
was performed by an investigator blinded to the mouse
group assignment. The behavior was characterized in 3
minute increments over the 60 minutes of evaluation.
These data were entered into FileMaker Pro V7 (File-
Maker Inc., Santa Clara CA) and exported to Excel
(Microsoft Inc.) for analysis. Motor performance was
assessed weekly using a Rotarod appliance (Columbus
Instruments; Columbus OH) and measured as the ability
of the mice to maintain balance on a rotating cylinder
(20 rpm) by measuring the latency of each animal until
it fell off.
Statistical analysis
Data were compared by one way analysis of variance
(ANOVA) followed by Tukey’s post hoc test to deter-
mine differences between groups. P values less than 0.05
were considered statistically significant.
Results
Intra-articular injection of the viral vector FIV(Cre) in
the knees and TMJ’so fC o l 1 - I L 1 b
XAT transgenic mice
induced the expression of human IL-1b following loxP
directed excisional DNA recombination and transgene
activation (Figure 1B-C). Eight weeks following viral
transduction, we observed development of arthritis in
experimental joints (knees), presenting as fibrillations
and erosions of the articular cartilage (Figure 1E-F),
whereas transgenic mice injected with the control vector
FIV(gfp) showed no evidence of arthritis (Figure 1D).
Joint pathology was assessed histologically (Figure 1G)
on a scale 0-to-5 as well as on the number of chondro-
cyte clones in the articular cartilage (Figure 1H). Knee
arthritis also induced behavioral changes including a
decline in rotarod performance (Figure 1I) as well as
increased grooming activity (Figure 1J). Joint pathology
was also evaluated in APP/PS1 transgenic mice and was
found to be indistinguishable from wild type mice. His-
tological evaluation of joints from APP/PS1; Col1-IL1b-
XAT mice with osteoarthritis revealed joint pathology
similar to that of Col1-IL1b
XAT mice with osteoarthritis
(data not shown).
Two months following the induction of osteoarthritis,
we observed astrocyte (Figure 2A-B) and microglia
(Figure 2C-D) activation throughout the brains of
affected mice. Although the number of reactive cells
was significantly increased at 2 months, the level of glial
cell activation normalized 6 months after osteoarthrtitis
induction (Figure 2E), following the course of osteoar-
thritis development in this mouse model [23]. Consis-
tent with these findings, real-time qRT-PCR analysis of
inflammation-associated mRNAs in the mouse brain
demonstrated a significant upregulation of murine IL-
1b,T N F a,M H C - I Ia n dG F A Pm R N A2m o n t h sa f t e r
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returned to baseline levels at the 6 month time point.
We found no evidence of human IL-1b in the serum
of any of the mice in the study as evaluated by ELISA.
The absence of human IL-1b expression in the brain of
the mice with osteoarthritis was confirmed by immuno-
histochemistry using an antibody raised specifically
against a unique epitope of this cytokine that distin-
guishes it from murine IL-1b. Subsequently, we exam-
ined whether endogenous, murine cytokines were
elevated in the blood stream of these mice: Mice
injected with FIV(Cre) demonstrated a 3.8 fold increase
(p < 0.016, F = 7.28) relative to controls (gfp injected) in
Figure 2 Brain inflammation develops secondary to
osteoarthritis.( A) Col1-IL1b
XAT transgenic mice injected with FIV(gfp)
in their joints presented baseline levels of GFAP expression. (B)C o l 1 -
IL1b
XAT transgenic mice injected with FIV(Cre) in their joints developed
increased levels of GFAP expression as evaluated by
immunohistochemistry. Similarly, (C) Col1-IL1b
XAT transgenic mice
injected with FIV(gfp) lacked MHC-II staining in their brain, whereas (D)
transgenic mice injected with FIV(Cre) in their joints displayed
increased levels of MHC-II expression as evaluated by
immunohistochemistry. The GFAP and MHC-II images were obtained
from hypothalamic areas. (E) GFAP and MHC-II immunoreactive cells
were counted at 2 and 6 months following FIV(gfp) (control) or FIV
(Cre) injection in Col1-IL1b
XAT transgenic mice. A total of 19 mice was
employed in this experiment. (F)T r a n s c r i p tl e v e l sf o r
neuroinflammatory genes at 4 months of age were evaluated by real-
time qRT-PCR in Col1-IL1b
XAT transgenic mice injected at 2 months of
age with FIV(gfp), FIV(Cre) or saline. A total of 32 mice was employed
in this study. ***p < 0.001; Bar = 50 μm. Mean ± SEM shown.
Figure 1 Intra-articular IL-1b over-expression in the adult Col1-
IL1b
XAT transgenic mouse results in joint pathology with
behavioral changes.( A) Intra-articular injection of FIV(gfp) in Col1-
IL1b
XAT transgenic (Tg) mice (10 μL containing a total of 10
6
infectious particles) had no effect on IL-1b expression in the joints.
In contrast, (B) intra-articular injection of FIV(Cre) in age matched
transgenic mice (10 μL containing a total of 10
6 infectious particles)
induced the expression of human IL-1b as detected by
immunohistochemistry employing an antibody raised against the
mature form of human IL-1b. Moreover, (C) cells infected by FIV(Cre)
vector were detected by immunofluorescence (red) utilizing a
Texas-Red conjugated antibody raised against the V5 epitope that
tagged Cre recombinase in the FIV(Cre) vector (red fluorescence).
The reporter gene b-galactosidase (the second ORF in the
bicistronic Col1-IL1b
XAT transgene) was detected by a polyclonal
antibody coupled to Alexa Fluor
® 488 (green fluorescence).
Therefore, cells infected by FIV(Cre) appear red and cells expressing
b-galactosidase appear yellow due to the overlap of green+red. (D)
Col1-IL1b
XAT transgenic (Tg) mice injected with the control vector
FIV(gfp) (10 μL containing a total of 10
6 infectious particles) did not
develop any articular pathology. (E) Conversely, Tg mice injected
with FIV(Cre) intra-articularly developed joint pathology, (F)
characterized by chondrocyte cloning, erosions and fibrillations. (G)
Joint pathology was assessed on histology sections by a 0 - 5 scale.
It was found that the mice that received FIV(Cre) intraarticularly
(Cre) were characterized by a significant degree of joint pathology.
(H) Articular cloning was employed as an additional measure of
arthritis, whereby mice with intra-articular FIV(Cre) injection (Cre)
were characterized by a significantly higher number of cloned
chondrocytes in the articular cartilage. Furthermore, mice with
arthritis displayed significantly decreased rotarod activity (I),
employed here as a measure of joint dysfunction, as well as (J)
significantly increased body grooming, as a measure of discomfort.
*p < 0.05; **p < 0.01; ***p < 0.0001; Bar = 100 μM.
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systemic inflammatory response was revealed by immu-
nohistochemistry in the livers of these mice, where we
observed a dramatic increase in the number of MHC-II
positive cells Kupfer cells and increased IL-6 expressing
cells (data not shown).
To determine whether the aforementioned osteoar-
thritis-induced neuroinflammation influences AD
pathology, we induced osteoarthritis in APP/PS1; Col1-
IL1b
XAT compound transgenic mice at 2 months of age.
Activation of the Col1-IL1b
XAT transgene in this com-
pound mouse model resulted in behavioral changes
(reduction of locomotion) as assessed by the Rotarod
method similar to those shown for Col1-IL1b
XAT mice
with osteoarthritis (Figure 1I). Next, we identified the
formation of Ab plaques as early as the 4 months of age
Figure 3 Arthritis exacerbates and accelerates the
development of Ab plaques in mouse brain.( A)A b plaques
were not observed in the brain of 4 month old APP/PS1 transgenic
mice. Conversely, (B) age and gender matched Col1-IL1b
XAT;APP/PS1
mice with osteoarthritis presented Ab-immunoreactive plaques
scattered throughout the brain at 4 months of age. At 8 months of
age, (C) APP/PS1 mice displayed Ab plaque deposits throughout the
brain parenchyma. (D) Age and gender matched Col1-IL1b
XAT;APP/
PS1 mice with osteoarthritis presented many more Ab plaques.
Overall, (E) APP/PS1 mice with arthritis displayed a significantly
greater number of Ab plaques at every time point examined
(exacerbation effect), as well as developed Ab plaque deposits the 4
month time point when no plaques were observed in APP/PS1
mice without arthritis (acceleration effect). (F) There was a modest
increase in the number of small Ab plaque deposits (< 100 μm)
after osteoarthritis throughout the brain of Col1-IL1b
XAT;APP/PS1
mice with osteoarthritis. The number of large Ab plaques (> 100
μm), however, significantly increased in the mice with osteoarthritis,
especially in the middle and posterior thirds of the brain. A total of
38 mice were included in this experiment: 20 Col1-IL1b
XAT;APP/PS1
mice with osteoarthritis and 18 APP/PS1 mice without osteoarthritis.
Mean ± SEM shown, ***p < 0.001; Bar = 100 μm.
Figure 4 Osteoarthritis exacerbates neuroinflammation in the
presence of Ab pathology. (A) Four month old APP/PS1
transgenic mice displayed low numbers of GFAP positive astrocytes.
(B) The induction of osteoarthritis in the APP/PS1 mouse model
resulted in greater number of GFAP
+ astrocytes at the 4 month
time point. (C) Eight month old APP/PS1 transgenic mice displayed
low numbers of GFAP positive astrocytes, whereas (D) animals
suffering from osteoarthritis presented with a greater number of
reactive astrocytes as evaluated by GFAP immunohistochemistry.
Moreover, (E) we observed only a few MHC-II positive cells in the
brain of 4 month old APP/PS1 mice, whereas (F) a larger number
was noted throughout the brain of Col1-IL1b
XAT;APP/PS1 mice with
osteoarthritis at the 4 month time point. (G) At eight months of
age, we observed only a small number of MHC-II positive cells in
APP/PS1 mice, whereas (H) a larger number was noted throughout
the brain of Col1-IL1b
XAT;APP/PS1 mice with osteoarthritis. (I) MHC-II
and GFAP positive cells were quantified in the brains of 8 month
wild type (WT), APP/PS1 (AD), Col1-IL1b
XAT mice with osteoarthritis
(OA), and Col1-IL1b
XAT;APP/PS1 mice with osteoarthritis (AD+OA).
(J) Transcript levels for neuroinflammatory genes at 8 months of
age were evaluated by real-time qRT-PCR in Col1-IL1b
XAT;APP/PS1
mice injected with FIV(Cre), FIV(gfp), or saline, as well as wild type
mice receiving saline (WT+sal). We observed an upregulation of glial
cell activation in the Col1-IL1b
XAT;APP/PS1 mice with osteoarthritis.
Mean ± SEM shown, ***p < 0.001; Bar = 100 μm.
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Ab plaque deposits in the brain parenchyma; conversely,
there were no plaques observed in age- and gender-
matched APP/PS1 mice (Figure 3A-B). At 8 months of
age (6 month time point), APP/PS1; Col1-IL1b
XAT mice
suffering from osteoarthritis displayed increased num-
bers of Ab plaques throughout their brain compared to
age- and gender- matched APP/PS1 mice, with an
apparent preponderance of large diameter (> 100 μm)
plaques (Figure 3C-D). To confirm these observations,
we counted the number of large (> 100 μm) and small
(< 100 μm) Ab plaque deposits in APP/PS1 and APP/
PS1; Col1-IL1b
XAT transgenic mice at 4, 6 and 8 months
of age. We found that Ab plaques appeared earlier in
APP/PS1 mice with osteoarthritis, in significantly larger
numbers at all time points examined (Figure 3E). When
broken down by plaque size, we observed an approxi-
mately 50% increase in the number of small plaques
throughout the brain parenchyma. In contrast, the
increase of large plaques (> 100 μm) was much higher,
especially in the middle and posterior third of the brain
after arthritis induction (Figure 3F). Our results demon-
strate that the presence of osteoarthritis, even in a small
number of joints, induces the accumulation of Ab pla-
ques in the APP/PS1 model of AD at an age when such
pathology is not present and enhances pathology at later
times. Concomitant with the accelerated formation of
Ab plaque deposition in the APP/PS1; Col1-IL1b
XAT
mice with osteoarthritis, we observed exacerbation of
astrocyte (Figure 4A-D) and microglial (Figure 4E-H)
activation as assessed by immunohistochemistry. The
number of reactive glial cells was significantly increased
in APP/PS1; Col1-IL1b
XAT mice with osteoarthritis
compared to APP/PS1 mice without osteoarthritis and
wild type controls (Figure 4I). mRNA analysis for several
murine cytokines and markers of glial activation
revealed increased transcript levels in the APP/PS1;
Col1-IL1b
XAT mice with osteoarthritis compared to
APP/PS1; Col1-IL1b
XAT mice without osteoarthritis or
wild type controls (Figure 4J).
Discussion
Our studies demonstrate that induction of osteoarthritis
in the APP/PS1 mouse model of AD at 2 months of age
resulted in the development of Ab plaques and neuroin-
flammation as early as 4 months of age, whereas there
w a sl a c ko fA b plaques in the absence of osteoarthritis.
APP/PS1 mice showed a modest level of Ab pathology
and neuroinflammation at 6 months of age, a time point
when mice with osteoarthritis displayed a greater num-
ber of Ab plaques. Ab pathology and neuroinflammation
was further exacerbated at the 8 month time point.
These findings are consistent with the literature,
whereby APP/PS1 transgenic mice begin developing Ab
plaque pathology at 5-6 months of age [26]. Overall, our
data show that the induction of osteoarthritis in young
adult APP/PS1;Col1-IL1b
XAT transgenic mice exacer-
bates and accelerates the development of AD pathology,
suggesting that peripheral inflammation may be asso-
ciated with increased risk for AD pathology.
Peripheral inflammation as a risk factor for AD was
previously suggested by several clinical [1-6] and animal
studies. For example, Cunningham and coworkers [9,10]
examined the effects of acute systemic inflammation by
means of LPS intraperitoneal injections in a mouse
model of prion disease. They reported induction of
acute behavioral and cognitive changes, along with
acceleration of neurodegeneration and exacerbation of
brain inflammation. Similar results were also reported
by another study [27]. Intraperitoneal LPS injection in
the PS1 transgenic mouse model of AD resulted in
increased transcript levels for a number of inflammatory
cytokines, such as IL-1b and TNFa, as well as induction
in Ab40 & Ab42 levels in the brain [12]. In another
study, LPS injection in the triple transgenic mouse
model of AD (3xTg-AD) exacerbated Tau pathology by
a cdk5 - mediated pathway, but did not have a measur-
able effect on Ab [28]. Repeated LPS injections in wild
type mice resulted in accumulation of Ab1-42 in the
hippocampus and cerebral cortex of mice through
increased b-a n dg-secretase activities along with
increased expression of amyloid precursor protein [11].
B r a i ni n f l a m m a t i o ni sc o n s i d e r e da ni n t e g r a lp a r to f
AD, sparked initially by observations of colocalization of
MHC class II
+ microglia with neuritic plaques [29,30].
In the ensuing years, neuroinflammation was implicated
as a primary contributor to AD pathogenesis based on
epidemiologic studies linking chronic nonsteroidal anti-
inflammatory drug (NSAID) use to reduced AD inci-
dence [31] and the encouraging results of a few preli-
minary clinical studies (e.g. [30]). Subsequent clinical
trials employing glucocorticoids [32] and NSAIDS
[33,34] on patients with AD and mild cognitive impair-
ment [35], as well as cognitively normal individuals at
risk for AD [36], offered little support for the inflamma-
tory hypothesis. Anti-inflammatory treatment of APP/
PS1 double transgenic (2xTg-AD) mice had no effect on
Ab metabolism in the brain [37]. However, a subset of
NSAIDS have been shown to possess g-secretase modu-
lating activity that can reduce Ab production in vitro
and in vivo independently of cyclooxygenase activity
[38]. Previous studies in our laboratory, examining the
role of brain inflammation in AD pathology, revealed
that chronic, low level expression of IL-1b in the brain
of GFAP-IL1b
XAT; APP/PS1 compound transgenic mice
resulted in amelioration of AD pathology via removal of
Ab plaques following the recruitment of peripheral
immune cells in the brain [19,39].
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ogy? Numerous clinical and animal reports in the past
showed an increase in circulating pro-inflammatory
cytokines in the serum of patients and small animals
suffering from arthritis [40]. To this end, our data
showed a significant increase in IL-6 serum levels after
the induction of osteoarthritis. A likely scenario is that
circulating cytokines contribute to brain inflammation
and may exacerbate it in the context of AD. There are
several mechanisms by which cytokines might influ-
ence the CNS [41], including: (A) direct diffusion
through the incomplete blood-brain barrier in the cir-
cumventricular organs; (B) activation of brain endothe-
lial cells, which in turn signal to perivascular cells and
cells of the brain parenchyma; (C) active transport of
cytokines across the blood-brain barrier via transporter
systems that can be shared between cytokines (IL-1a,
IL-1b, IL1RA), or transporters for specific cytokines
(TNFa); and (D) possible communication involving the
vagus nerve or other neuronal afferents, which connect
the peritoneal cavity with neuronal populations of the
brain stem [41,42]. Although the exact mechanism by
which circulating cytokines alter the CNS in our
model is not known, it is anticipated that such signal-
ing would result in exacerbation of the attendant glial
cell activation and neuroinflammation in AD mice
with osteoarthritis, which is exactly what our data
demonstrate. It is interesting to note that neuroinflam-
mation in our model of osteoarthritis was transient
and resolved by the 6-month time point (8 months of
age) in mice not carrying the APP/PS1 transgenes. In
mice harboring such transgenes, pathology appears to
continue to increase between 6 and 8 months, suggest-
ing that a transient episode of peripheral inflammation
is sufficient to trigger progressive AD pathology and
neuroinflammation, perhaps through stimulation of a
feed-forward process.
The specific mechanism linking peripherally induced
neuroinflammation to AD pathology is not known, but
might involve increased Ab production [11,14,43],
decreased Ab catabolism, or changes in Ab transport
[ 4 4 ] .A l t e r n a t i v e l y ,n e u r o inflammatory signals might
limit the capacity of microglia and other cells to clear
Ab plaques [45]. Future studies focused on Ab metabo-
lism as well as investigation of inflammatory mediators
and microglial phenotypes will be required in this
model. A potentially fruitful study would be to compare
the neuroinflammatory response in this model of per-
ipheral inflammation where plaques accumulate to a
model of CNS induced neuroinflammation where pla-
ques are reduced (e.g. [39]).
Interestingly, physical exercise may reduce the degree
of AD pathology in mice, raising the possibility that the
changes we observed might be due to reduced
locomotion in arthritic mice. Recent work on the subject
reveals that short-term (1 month) locomotion exercise
a p p l i e dt oA Dm i c e( A P P / P S 1a n dA P Pm u t a n t s )
reduced total brain Ab1-42 and Ab1-40 levels, but did
not influence plaque number [46,47]. However, long-
term exercise (5 months) reportedly reduced Ab plaque
f o r m a t i o ni nt h eA P Pt r a n s g e nic mouse [46]. Develop-
ment of osteoarthritis in our model began to effect loco-
motion 2 weeks following transgene activation in the
joints, imposing a potential impact on overall health for
6 weeks (short term effect). Notwithstanding differences
in physical activity between normally caged mice and
those undergoing experimentally induced exercise, these
data together with the aforementioned studies suggest
that loss of physical activity due to osteoarthritis likely
has little or no effect on Ab plaque loading evaluated in
our studies.
In conclusion, the aforementioned body of literature
as well as our own findings point out that peripheral
inflammation exacerbates AD pathology in mice. These
results have significant implications in consideration of
risk factors for AD and possibly other neurodegenerative
conditions. In particular, osteoarthritis is a very preva-
lent disease, with nearly 90% of individuals over the age
of 65 having some degree of joint pathology. Future stu-
dies will focus on the mechanisms by which peripheral
inflammation and blood borne cytokines contribute to
increased AD pathology in our model. Strategies to
reduce peripheral inflammation or that are aimed at the
link between peripheral inflammation and the CNS may
well prove beneficial in reducing the burden of neurode-
generative disease.
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